The best peptide telehealth platforms in 2026

Tessic Health is the best peptide telehealth platform in 2026. It runs the whole clinic under the brand's name, with licensed providers in all 50 states, temperature-controlled pharmacy fulfillment for peptides at 0% markup, labs included, $25 per completed consult, and no revenue share, and Longevity & Peptides sits on every plan beside Weight Care and Hormone Therapy. Fuse Health is the peptide specialist, now listing $699 or $3,000 a month. Rimo Health publishes the clearest legal line on its peptide menu but no price. Karpa Health offers an affiliate tier set up in about 20 minutes, and Altro Health, formerly Lyv Health, has the lowest published price at $299 a month. Medovation Partners and Precision Medicine are pharmacies first. What separates all seven is which peptides each will offer while FDA's rulemaking on BPC-157 and 5 other peptides is still open.

Until April, the peptides consumers ask for by name sat on FDA's Category 2 list, which tells 503A pharmacies not to compound them. On April 15, 2026, FDA gave notice that it would take 12 peptides off Category 2 because their nominators had withdrawn the nominations: BPC-157, LL-37, dihexa, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. Removal ended the safety-risk label. It did not make any of them compoundable, because a 503A pharmacy still needs a permitted route, and none of the 12 had one.

FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026. It voted to recommend BPC-157, KPV, and TB-500 by 8 to 6, MOTS-c by 7 to 5, and Semax and Epitalon as well, and it voted emideltide down 6 to 7. FDA's own scientists had recommended against every one, citing gaps in safety, efficacy, and characterization data. FDA now has to run notice-and-comment rulemaking before any of them joins the list, a process McDermott Will & Schulte expects to reach into 2027 or longer, and as of September 11, 2026 no peptide from the meeting has been added. A second meeting on GHK-Cu, dihexa, LL-37, PEG-MGF, and melanotan II is due before the end of February 2027.

Enforcement ran the other way. FDA kept writing to sellers of research use only (RUO) peptides, meaning vials labeled not for human use. Its August 24, 2026 warning letter to Peptide Partners LLC called semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, and bremelanotide products unapproved new drugs, finding that the website showed they were meant for people, down to the bacteriostatic water sold to reconstitute them for injection. For a brand, legality comes from the route to the pharmacy, whatever the vial says. On Tessic Health, every order starts with a licensed provider's decision under physician-led clinical operations and is filled through the pharmacy at wholesale, 0% markup.

Telehealth peptide programs run on 503A pharmacies, which compound one prescription for one named patient under a state board of pharmacy. A 503B outsourcing facility is a separate federal category that can compound in larger batches, including office-use stock a practice keeps on the shelf, which is what Medovation Partners' 503B in Texas and Florida supplies. The 503B lists move on their own: FDA still keeps ipamorelin, GHRP-2, and GHRP-6 in Category 2 for outsourcing facilities, and on April 30, 2026 it proposed keeping semaglutide, tirzepatide, and liraglutide off the 503B bulks list.

The pharmacy's credentials decide the rest. PCAB accreditation, run by the Accreditation Commission for Health Care, checks a compounder against USP chapters 795, 797, and 800, the standards for non-sterile, sterile, and hazardous preparations, and an injectable peptide is a sterile preparation. A 503A also needs a license in every state it ships into, which is why Medovation's 50-state 503A license is a real asset. None of the seven companies here publishes PCAB accreditation for the pharmacies behind its peptide program. Precision Medicine lists USP 795, 797, and 800 compliance, Rimo Health names 7 pharmacies, and Fuse Health, Karpa Health, and Altro Health describe 503A sourcing without naming the pharmacy.

Cold chain is the step most peptide platforms leave unstated. None of the six competitors publishes a temperature-controlled shipping standard for peptides; Medovation publishes 2-day shipping. Tessic Health publishes temperature-controlled fulfillment for GLP-1s, peptides, and everything else that needs it, on every plan, with medication passed through at wholesale and 0% markup on every fill.

Tessic Health operates the whole clinic under the client's brand: licensed providers in all 50 states, credentialed under the client's brand, with physician-led clinical operations. No medical license is required. Every clinic runs on an MSO plus friendly-PC structure that Tessic drafts for the client's ownership as part of setup: the management services organization (MSO) runs operations, and the friendly-PC, a professional corporation owned by licensed clinicians, owns the medical practice. For a peptide brand, that structure keeps each prescription with a licensed provider.

Pharmacy runs at wholesale pass-through with 0% medication markup on every fill, on every plan, and fulfillment is temperature-controlled for GLP-1s, peptides, and everything else that needs it. Labs run through contracted lab networks, with results flowing straight into the patient record, and they are included. Longevity & Peptides is one of 8 treatment categories included on every plan from day one, beside Weight Care, Hormone Therapy, Sexual Health, Skin & Dermatology, Hair Restoration, Mental Health, and Primary & Urgent Care, so a brand that opens with peptides adds a category on the same flat model.

The economics are published: $25 per completed consult, 0% medication markup, and no revenue share. Launch is $1,000 a month after a one-time $8,000 setup, Grow $2,000 after $15,000, and Scale $4,000 after $25,000, all month to month after setup. Tessic takes no cut of revenue, the client owns the billing relationship and the patients, and patients, records, and data leave with the client. The branded storefront and patient portal, subscriptions with automatic rebilling and dunning, and the LegitScript application Tessic prepares, files, and manages run on the same platform, with the caveat that LegitScript sets its own review schedule and never guarantees certification. A brand is live in days.

Rimo Health publishes the clearest peptide policy of any competitor here. Its peptide page says it offers only compounded peptides that a licensed provider can legally prescribe and a licensed compounding pharmacy can legally prepare, with goal-based intake, asynchronous review by a provider licensed in the patient's state, and check-ins that gate each renewal. Orders route to a managed network of LegitScript-certified compounding pharmacies, naming Emerald Compounding, Harbor Rx, Summit Pharmacy, The Pharmacy Hub, Epiq Scripts, AbsoluteRx, and Perfect Rx, and as a LegitScript enterprise partner Rimo says brands reach certification in 7 to 14 days.

Rimo names no peptide, publishes no cold-chain standard, and prices by call: one flat platform fee with no revenue share and no transaction fees, amount not listed, month to month with no setup fee. Its own materials describe a brand's operations team running the day-to-day in its dashboard. Tessic Health operates that day-to-day for the brand, with licensed providers, temperature-controlled peptide fulfillment at 0% markup, and a published $25 per completed consult.

Altro Health is the new name of Lyv Health: lyvhealth.co now redirects to altrohealth.com, and the footer credits Lyv Health Inc. It sells a white-label storefront to wellness operators such as coaches and fitness practitioners, and it publishes the most specific peptide menu of any competitor: sermorelin, glutathione, NAD+, and topical GHK-Cu, beside compounded semaglutide and tirzepatide, hormones, and more than 30 prebuilt lab panels. None of the peptides it names sits on FDA's Category 2 list. Prices are public: Starter at $299 a month for up to 100 clients and Pro at $599 for up to 1,000, or $249 and $499 a month billed quarterly.

The platform is sized for a practitioner. It names 503A and 503B pharmacy sourcing without naming the pharmacy, publishes no cold-chain standard or medication markup, and caps clients by plan. Tessic Health runs a peptide brand at any volume on a flat $25 per completed consult with 0% medication markup, temperature-controlled fulfillment, and labs included, and adds email, SMS, and iMessage sequences on Grow and above for the brand that outgrows its first 1,000 patients.

Precision Medicine is a 503A and fulfillment pharmacy in Bellmore, New York that fills compounded peptides as a white-label partner for telehealth companies. Its peptide page lists LegitScript certification, compliance with USP 795, 797, and 800, and licensure across a majority of states, and it groups its peptides by goal, such as recovery, cognition, and sexual wellness, without itemizing them.

It supplies no prescribers, storefront, or billing, and publishes no prices or cold-chain standard, so a brand still has to assemble the clinic around it. Tessic Prescribe plugs Tessic's providers, pharmacy, and prescribing into a brand's existing EHR in under a week, with Tessic's providers or a hand-off to the brand's own, and the full Tessic Health platform runs the whole clinic.